BioMarin Q3 2026 Revenue Jumps 32% to $1.025 Billion
BioMarin posted strong third-quarter results, with total revenues hitting $1.025 billion, led by surging metabolic and skeletal conditions sales.
BioMarin Pharmaceutical reported third-quarter 2026 total revenues of $1.025 billion, a 32% increase compared with the same period a year earlier, according to the company's latest financial results.
The growth was driven primarily by a 44% year-over-year jump in revenue from metabolic conditions treatments, while the skeletal conditions segment posted a more modest but still notable 12% increase over the same stretch.
Read more Securitize Acquires River One to Bridge Stablecoins and Asset-Backed Finance →
Despite the strong top-line performance, BioMarin revised its full-year 2026 guidance, citing uncertainty around order timing as well as the financial impact of two acquired in-process research assets. The guidance adjustment signals that management expects some near-term variability even as underlying commercial demand remains robust.
The combination of a billion-dollar quarterly revenue milestone and upward momentum across two key therapeutic categories reflects BioMarin's continued push to expand its rare-disease portfolio. Analysts will likely focus on whether the order-timing uncertainty represents a structural headwind or a temporary scheduling factor heading into the fourth quarter.
Continue reading at All Financial Services & Investing.
